Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2005-01-18
2010-02-23
Steele, Amber D. (Department: 1639)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C506S007000
Reexamination Certificate
active
07666583
ABSTRACT:
The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
REFERENCES:
patent: 5583110 (1996-12-01), Altchek et al.
patent: 6071914 (2000-06-01), Cincotta et al.
patent: 6235474 (2001-05-01), Feinberg
patent: 6642009 (2003-11-01), Hung
patent: 2003/0044862 (2003-03-01), Giaccia et al.
patent: 2003/0180747 (2003-09-01), Hruban et al.
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0219812 (2003-11-01), Quay et al.
patent: 2003/0232398 (2003-12-01), MacMurray et al.
patent: 2004/0023288 (2004-02-01), Ridder et al.
patent: 2004/0072189 (2004-04-01), Smith et al.
patent: 2005/0069963 (2005-03-01), Lokshin et al.
patent: 1 256 354 (2002-11-01), None
patent: 02083337 (1990-03-01), None
patent: WO 94/19004 (1994-09-01), None
patent: WO 00/55629 (2000-09-01), None
patent: WO01/40271 (2001-06-01), None
patent: WO01/53837 (2001-07-01), None
patent: WO 01/54713 (2001-08-01), None
patent: WO 01/70985 (2001-09-01), None
patent: WO03/005197 (2003-06-01), None
patent: WO 03/051917 (2003-06-01), None
patent: WO03/102148 (2003-12-01), None
Sancak et al., Internal Medicine Journal, 2004, 34: 310-315.
Jacobs et al., Molecular & Cellular Proteomics, 2004, 3.4: 355-366.
Taylor et al., 2001, Cancer Screening in a High Risk Population: a Clinical Trial, Ultrasound in Med. & Biol., 27(4): 461-466.
Mor et al., 2005, Serum Protien Markers for Early Detection of Ovarian Cancer, PNAS, 102(21): 7677-7682.
Zhang et al., Cancer Research, 2004, 64: 5882-5890.
Baron-Hay et al., Clinical Cancer Research, 2004, 10: 1796-1806.
Jha et al., Int. J. Gynecol. Obstet., 1991, 36: 33-38.
Tessitore et al., Int. J. Mol. Med., 2000, 5: 421-426.
Zhang et al., Mol. Cell. Biol., 2003, 23(18): 6507-6519.
Sawiris et al., 2002, Development of a Highly Specialized cDNA Array for the Study and Diagnosis of Epithelial Ovarian Cancer, Cancer Research, 62: 2923-2928. 20 additional pages for the gene listing.
Choi et al., 2005 (epub Nov. 2, 2004), Expression of Leptin Receptors and Potential Effects of Leptin on the Cell Growth and Activation of Mitogen-activated Protein Kinases in Ovarain Cancer Cells, 90(1): 207-210.
Schorge et al., 2004, Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarain Cancer, Clinical Cancer Research, 10: 3474-3478.
Yoshida et al., 1998, Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alkaline phosphate and neuron-specific enolase associated with elevation of serum prolactin level, European Journal of Obsterics & Gynecology, 81: 123-128.
Baron-Hay et al., 2004, “Elevated serum-insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer,” Clin. Cancer Res. 10(5):1796-1806.
Bowen et al., 2000, “Downregulation of long-form prolactin receptor mRNA during prolactin-induced regression,” Eur. J. Endocrinol. 143(2):285-292.
Brakora et al., 2004, “Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer,” Gynecol. Oncol. 93(2):361-365.
Crump et al., 2000, “Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening,” Cancer Epidemiol. Biomarkers Prev 9(10):1107-1111.
DeSouza et al., 2004, “Fastin ghrelin levels in physically active women: relationship with menstrual disturbances and metabolic hormones,” J. Clin. Endocrinol. Metab. 89(7):3536-3542.
Dixit et al., 2004, “Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells,” J. Clin. Invest. 114(1):57-66.
Furger et al., 2001, “The functional and clinical roles of osteopontin in cancer and metastasis,” Curr. Mol. Med. 1(5):621-632.
Gutzman et al., 2004, “Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells,” Mol. Endocrinol. 18(12):3064-3075.
Ho, 2003, “Estrogen, Progesterone and Epithelial Ovarian Cancer,” Reprod. Biol and Endocrin 1:73.
Ishikawa et al., 2004, “Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer,” Clin. Cancer Res. 10(13):4325-4331.
Jacobs and Menon, 2004, “Progress and challenges in screening for early detection of ovarian cancer,” Mol. Cell Proteomics 3(4):355-366.
Jha et al., 1991, “Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy,” Int. J. Gynaecol. Obstet. 36(1):33-38.
Kitawaki et al., 1999, “Leptin directly stimulates aromatase activity in human lutenized granulosa cells,” Mol. Human Reprod. 5(8):708-713.
Koopmann et al., 2004, “Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma,” Cancer Epidemiol. Biomarkers Prev. 13(3):487-491.
Lu et al., 2004, Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis, Clin Cancer Res. 10(10):3291-3300.
Malaguarnera et al., “Prolactin increases HO-1 expression and induces VEGF production in human macrophages,” J. Cell. Biochem. 93(1):197-206.
McIntosh et al., 2004, “Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma,” Gynecol. Oncol. 95(1):9-15.
Menon, 2004, “Ovarian cancer screening,” Cmaj 171(4):323-324.
Motta el al., 2004, “Leptin and prolactin modulate the expression of SOCS-1 in association with interleuki-6 and tumor necrosis factor-alpha in mammary cells: a role in differential secretory epithelium,” Regul Pept. 121(1-3):163-170.
Mujagic and Mujagic, 2004, “Importance of serum prolactin determination in metastatic breast cancer patients,” Croat. Med. J. 45(2)176-180.
O'Regan et al., 2002, “Osteopontin as a biomarker for ovarian cancer,” JAMA 287(24):3208-3210.
Oberbeck, 2004, “Therapeutic implications of immune-endocrine interactions in the critically ill patients,” Curr. Drug. Targets Immune Endocr. Metabol. Disord. 4(2):129-139.
Perks et al., 2004, “Prolactin acts as a potent survival factor for human breast cancer cell lines,” Br. J. Cancer. 91(2):305-311.
Perumal et al., 1998, “Prolactin as a tumour marker in cancer of the cervix,” J. Obstet. Gynaecol. 18(3):260-262.
Petricoin et al., 2002, “Use of proteomic patters in serum to identify ovarian cancer,” Lancet 359(9306):572-577.
Plebani et al., 1996, “Serum tumor markers in colorectal cancer staging , grading, and follow-up,” J. Surg. Oncol. 62(4):239-244.
Rittling and Chambers, 2004, “Role of osteopontin in tumour progression,” Br. J. Cancer 90(10):1877-1881.
Rose et al., 2004, “Obesity, adipocytokines, and insulin resistance in breast cancer,” Obesity Reviews 5(3):153.
Sancak et al., 2004, “No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery,” Intern. Med. J. 34(6):310-315.
Santin et al., 2004, “Gene expression profiles in primary ovarian serous papillar tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy,” Int. J. Cancer 112(1):14-25.
Schorge et al., 2004, “Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer,” Clin. Cancer Res. 10(1):3474-3478.
Schweitzer et al., 2002, “Multiplexed protein profiling on microarrays by rolling-circle amplifica
Bray-Ward Patricia
Mor Gil G.
Ward David C.
Steele Amber D.
Wolf Greenfield & Sacks P.C.
Yale University
LandOfFree
Identification of cancer protein biomarkers using proteomic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identification of cancer protein biomarkers using proteomic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of cancer protein biomarkers using proteomic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204718